Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30496
Title: Intensive management of obesity in people with Prader-Willi syndrome.
Austin Authors: Nolan, Brendan James ;Proietto, Joseph ;Sumithran, Priya 
Affiliation: Department of Medicine (St Vincent's), University of Melbourne, Melbourne, VIC, Australia..
Endocrinology
Medicine (University of Melbourne)
Issue Date: Jun-2022
Date: 2022
Publication information: Endocrine 2022; 77(1): 57-62
Abstract: Prader-Willi syndrome (PWS) is characterised by childhood-onset hyperphagia and obesity however limited data are available to guide treatment of obesity in this population. We aimed to evaluate the safety, tolerability, and efficacy of intensive medical weight loss interventions (very-low-energy diets [VLED] and/or pharmacotherapy) in individuals with PWS attending a specialist obesity management service. A retrospective audit was undertaken of individuals with PWS attending the Austin Health Weight Control Clinic between January 2010-April 2021. Main outcome measures were weight outcomes, duration of use, and adverse effects. Data were available for 18 patients, of whom 15 were treated with intensive weight loss interventions. Median (interquartile range, IQR) age at baseline was 20 years (19-32) with median body weight 90 kg (75-118) and BMI 37 kg/m2 (30-51). Median weight loss during VLED (n = 7) was 14 kg (1-20 kg) over 60 weeks. Median weight loss with phentermine-topiramate (n = 7) was 17 kg (IQR 9-19 kg) over 56 weeks. Median weight loss with liraglutide 0.6-3 mg (n = 7), prescribed with topiramate in 3 individuals, was 9 kg (2-14 kg) over 96 weeks. Naltrexone-bupropion resulted in weight loss in 2 of 4 individuals. Thirteen individuals achieved ≥10% weight loss but only 5 individuals maintained ≥10% weight loss at last follow-up. Five individuals discontinued pharmacotherapy due to adverse effects. VLED and pharmacotherapy can achieve substantial weight loss in some individuals with PWS though non-adherence results in substantial weight regain. Adverse effects were ascribed to phentermine and topiramate, whereas liraglutide was well-tolerated in this population.
URI: https://ahro.austin.org.au/austinjspui/handle/1/30496
DOI: 10.1007/s12020-022-03064-1
ORCID: http://orcid.org/0000-0001-8836-165X
http://orcid.org/0000-0002-8517-2076
http://orcid.org/0000-0002-9576-1050
Journal: Endocrine
PubMed URL: 35524875
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35524875/
Type: Journal Article
Subjects: Obesity
Obesity pharmacotherapy
Prader-Willi syndrome
VLED
Weight loss
Appears in Collections:Journal articles

Show full item record

Page view(s)

56
checked on Oct 11, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.